Tag: Atezolizumab
Modest activity of atezolizumab plus bevacizumab in Child-Pugh B HCC
Single-cell spatial analysis can predict response to neoadjuvant immunotherapy
Immune chemo-sensitisation looks promising in microsatellite-stable mCRC
Adjuvant atezolizumab lowers relapse rate in resected NSCLC
Atezolizumab promising for treating NSCLC brain metastases
Real-world data shows inferior survival compared with IMpower150 results
Trial explores potential benefit of adding atezolizumab to usual care for mesothelioma
ctDNA can guide adjuvant immunotherapy in muscle-invasive bladder cancer
Immune-related adverse events are associated with efficacy of atezolizumab in patients with advanced NSCLC
Atezolizumab with SABR for high-risk early-stage NSCLC: initial results
Landmark OS for HCC, updated IMbrave150 data
Primary analysis from IMvigor010, adjuvant atezolizumab in high risk muscle-invasive urothelial carcinoma
No higher pathologic complete response with atezolizumab added to chemotherapy
PFS extension with immunotherapy + chemotherapy in urothelial cancer
Longer OS with atezolizumab + carboplatin + nab-paclitaxel in advanced squamous NSCLC
ImPassion130 brings breast cancer into the immunotherapy era
Combo I-O plus chemotherapy
Other I-O combinations
Treatment options in early NSCLC
Immunotherapy in SCLC: trial data
Largest safety study of its kind with atezolizumab in metastatic bladder cancer
Bladder cancer in young patients
Combination therapies: Where are we in 2018?
